Haemonetics Stock Price, News & Analysis (NYSE:HAE)

$56.48 -0.08 (-0.14 %)
(As of 12/11/2017 08:13 AM ET)
Previous Close$56.56
Today's Range$56.23 - $57.18
52-Week Range$36.44 - $58.99
Volume333,900 shs
Average Volume358,078 shs
Market Capitalization$2.98 billion
P/E Ratio34.65
Dividend YieldN/A
Beta0.99

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100

Debt

Debt-to-Equity Ratio0.22%
Current Ratio2.17%
Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio34.65
Forward P/E Ratio33.22
P/E Growth4.25

Sales & Book Value

Annual Sales$886.12 million
Price / Sales3.37
Cash Flow$3.25 per share
Price / Cash17.38
Book Value$14.22 per share
Price / Book3.97

Profitability

Trailing EPS$0.08
Net Income$-26,260,000.00
Net Margins0.50%
Return on Equity11.16%
Return on Assets6.79%

Miscellaneous

Employees3,107
Outstanding Shares52,820,000

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How were Haemonetics' earnings last quarter?

Haemonetics Corporation (NYSE:HAE) released its quarterly earnings data on Tuesday, November, 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.07. The medical instruments supplier had revenue of $225.40 million for the quarter, compared to analyst estimates of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. View Haemonetics' Earnings History.

When will Haemonetics make its next earnings announcement?

Haemonetics is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY18 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.61. The company issued revenue guidance of to approximate FY17 of $886.1 million, compared to the consensus revenue estimate of $889.45 million.

Where is Haemonetics' stock going? Where will Haemonetics' stock price be in 2017?

5 Wall Street analysts have issued 12 month price objectives for Haemonetics' shares. Their predictions range from $48.00 to $57.00. On average, they expect Haemonetics' stock price to reach $51.20 in the next twelve months. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:

  • Christopher Simon, President, Chief Executive Officer, Director (Age 53)
  • William P. Burke, Chief Financial Officer, Executive Vice President (Age 49)
  • David J. Wilson, President - Plasma Business Unit
  • Michelle Basil, Executive Vice President, General Counsel (Age 45)
  • Neil Ryding, Executive Vice President, Global Operations (Age 56)
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board (Age 68)
  • Robert E. Abernathy, Director (Age 62)
  • Catherine M. Burzik, Independent Director (Age 66)
  • Charles J. Dockendorff, Independent Director (Age 62)
  • Susan Bartlett Foote, Independent Director (Age 70)

Who owns Haemonetics stock?

Haemonetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (5.22%), Victory Capital Management Inc. (4.59%), Neuberger Berman Group LLC (3.89%), Fuller & Thaler Asset Management Inc. (3.48%), Dimensional Fund Advisors LP (3.30%) and Van Berkom & Associates Inc. (2.28%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

Who sold Haemonetics stock? Who is selling Haemonetics stock?

Haemonetics' stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN, Magnetar Financial LLC, Hermes Investment Management Ltd., Stevens Capital Management LP, Anchor Capital Advisors LLC and American Capital Management Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.

Who bought Haemonetics stock? Who is buying Haemonetics stock?

Haemonetics' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Neuberger Berman Group LLC, Macquarie Group Ltd., JPMorgan Chase & Co., Schroder Investment Management Group, GSA Capital Partners LLP, Los Angeles Capital Management & Equity Research Inc. and Boston Advisors LLC. View Insider Buying and Selling for Haemonetics.

How do I buy Haemonetics stock?

Shares of Haemonetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of Haemonetics stock can currently be purchased for approximately $56.48.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $2.98 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Haemonetics (NYSE:HAE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.182.202.00
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.11$41.70$38.38$34.86
Price Target Upside: 20.52% downside23.12% downside9.47% downside18.82% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$43.00 -> $51.00N/AView Rating Details
11/8/2017Craig HallumReiterated RatingHold$40.00 -> $50.00N/AView Rating Details
11/8/2017Barrington ResearchBoost Price TargetOutperform$48.00 -> $57.00N/AView Rating Details
7/27/2017Jefferies GroupReiterated RatingBuy$48.00HighView Rating Details
7/13/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$50.00HighView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016BenchmarkBoost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs GroupUpgradeSell -> Neutral$29.00N/AView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
11/7/2017Q2 2018$0.41$0.48$219.12 million$225.40 millionViewN/AView Earnings Details
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Haemonetics (NYSE:HAE) Earnings Estimates

2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.61
2019 EPS Consensus Estimate: $1.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.37$0.42$0.39
Q4 20173$0.35$0.38$0.36
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.41$0.46$0.43
Q4 20182$0.43$0.45$0.44
Q1 20191$0.41$0.41$0.41
Q2 20191$0.46$0.46$0.46
Q3 20191$0.46$0.46$0.46
Q4 20191$0.43$0.43$0.43
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics (NYSE:HAE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Pedro P GranadilloDirectorSell7,118$57.06$406,153.08View SEC Filing  
11/16/2017Ronald G GelbmanDirectorSell5,440$56.69$308,393.60View SEC Filing  
11/14/2017Willaim P BurkeCFOSell13,193$54.04$712,949.72View SEC Filing  
11/13/2017Dan GoldsteinCAOSell4,691$54.93$257,676.63View SEC Filing  
11/10/2017Susan Bartlett FooteDirectorSell16,926$54.19$917,219.94View SEC Filing  
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.43View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.90View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Haemonetics (NYSE HAE) News Headlines

Source:
DateHeadline
Haemonetics Corporation (HAE) Given Consensus Rating of "Hold" by AnalystsHaemonetics Corporation (HAE) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 8 at 1:52 AM
Haemonetics Corporation (HAE) Director Pedro P. Granadillo Sells 7,118 SharesHaemonetics Corporation (HAE) Director Pedro P. Granadillo Sells 7,118 Shares
www.americanbankingnews.com - December 4 at 6:12 PM
$226.94 Million in Sales Expected for Haemonetics Corporation (HAE) This Quarter$226.94 Million in Sales Expected for Haemonetics Corporation (HAE) This Quarter
www.americanbankingnews.com - November 26 at 10:08 AM
Haemonetics (HAE) at 52-Week High: Whats Driving the Stock?Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
www.zacks.com - November 20 at 7:51 PM
Zacks Investment Research Lowers Haemonetics Corporation (HAE) to HoldZacks Investment Research Lowers Haemonetics Corporation (HAE) to Hold
www.americanbankingnews.com - November 20 at 1:32 PM
Insider Selling: Haemonetics Co. (HAE) Director Sells 5,440 Shares of StockInsider Selling: Haemonetics Co. (HAE) Director Sells 5,440 Shares of Stock
www.americanbankingnews.com - November 17 at 8:37 PM
Zacks Investment Research Upgrades Haemonetics Corporation (HAE) to "Buy"Zacks Investment Research Upgrades Haemonetics Corporation (HAE) to "Buy"
www.americanbankingnews.com - November 17 at 1:54 PM
Haemonetics Co. (HAE) CFO Willaim P. Burke Sells 13,193 SharesHaemonetics Co. (HAE) CFO Willaim P. Burke Sells 13,193 Shares
www.americanbankingnews.com - November 16 at 8:12 PM
Haemonetics Corporation (HAE) CAO Dan Goldstein Sells 4,691 SharesHaemonetics Corporation (HAE) CAO Dan Goldstein Sells 4,691 Shares
www.americanbankingnews.com - November 15 at 8:44 PM
Haemonetics Corporation (HAE) Director Susan Bartlett Foote Sells 16,926 SharesHaemonetics Corporation (HAE) Director Susan Bartlett Foote Sells 16,926 Shares
www.americanbankingnews.com - November 14 at 8:04 PM
Haemonetics Corporation (HAE) Receives Consensus Recommendation of "Hold" from AnalystsHaemonetics Corporation (HAE) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 2:34 AM
Haemonetics Shows Market Leadership With Jump To 91 RS RatingHaemonetics Shows Market Leadership With Jump To 91 RS Rating
finance.yahoo.com - November 11 at 5:35 AM
Jefferies Group Weighs in on Haemonetics Corporations Q3 2018 Earnings (HAE)Jefferies Group Weighs in on Haemonetics Corporation's Q3 2018 Earnings (HAE)
www.americanbankingnews.com - November 10 at 4:20 PM
Q3 2018 Earnings Estimate for Haemonetics Corporation Issued By Barrington Research (HAE)Q3 2018 Earnings Estimate for Haemonetics Corporation Issued By Barrington Research (HAE)
www.americanbankingnews.com - November 10 at 4:20 PM
Research Analysts Issue Forecasts for Haemonetics Corporations FY2018 Earnings (HAE)Research Analysts Issue Forecasts for Haemonetics Corporation's FY2018 Earnings (HAE)
www.americanbankingnews.com - November 9 at 2:24 PM
FY2018 Earnings Forecast for Haemonetics Corporation (HAE) Issued By William BlairFY2018 Earnings Forecast for Haemonetics Corporation (HAE) Issued By William Blair
www.americanbankingnews.com - November 9 at 2:24 PM
Haemonetics (HAE) in Focus: Stock Moves 10% HigherHaemonetics (HAE) in Focus: Stock Moves 10% Higher
www.zacks.com - November 9 at 6:28 AM
Craig Hallum Reaffirms "Hold" Rating for Haemonetics Corporation (HAE)Craig Hallum Reaffirms "Hold" Rating for Haemonetics Corporation (HAE)
www.americanbankingnews.com - November 8 at 4:30 PM
Haemonetics Corp. (HAE) Leaped To A New High On Strong Q2 EarningsHaemonetics Corp. (HAE) Leaped To A New High On Strong Q2 Earnings
www.rttnews.com - November 8 at 8:49 AM
Haemonetics Corp. (HAE) Leaped To A New High On Strong Q2 EarningsHaemonetics Corp. (HAE) Leaped To A New High On Strong Q2 Earnings
www.rttnews.com - November 8 at 8:49 AM
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View UpHaemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
www.zacks.com - November 8 at 8:49 AM
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View UpHaemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
www.zacks.com - November 8 at 8:49 AM
Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics tops Street 2Q forecastsHaemonetics tops Street 2Q forecasts
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics tops Street 2Q forecastsHaemonetics tops Street 2Q forecasts
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics announces plans to cut 350 jobsHaemonetics announces plans to cut 350 jobs
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics announces plans to cut 350 jobsHaemonetics announces plans to cut 350 jobs
finance.yahoo.com - November 8 at 8:49 AM
ETFs with exposure to Haemonetics Corp. : November 7, 2017ETFs with exposure to Haemonetics Corp. : November 7, 2017
finance.yahoo.com - November 8 at 8:49 AM
ETFs with exposure to Haemonetics Corp. : November 7, 2017ETFs with exposure to Haemonetics Corp. : November 7, 2017
finance.yahoo.com - November 8 at 8:49 AM
Edited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 8:49 AM
Edited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics Corporation (HAE) Releases  Earnings Results, Beats Estimates By $0.07 EPSHaemonetics Corporation (HAE) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 7 at 12:23 PM
Haemonetics Corporation (HAE) Updates FY18 Earnings GuidanceHaemonetics Corporation (HAE) Updates FY18 Earnings Guidance
www.americanbankingnews.com - November 7 at 10:29 AM
$0.42 Earnings Per Share Expected for Haemonetics Corporation (HAE) This Quarter$0.42 Earnings Per Share Expected for Haemonetics Corporation (HAE) This Quarter
www.americanbankingnews.com - November 5 at 1:16 PM
Haemonetics Corporation (HAE) Set to Announce Earnings on TuesdayHaemonetics Corporation (HAE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:34 AM
Haemonetics Corporation (HAE) Sees Significant Drop in Short InterestHaemonetics Corporation (HAE) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 31 at 1:50 AM
Haemonetics Corporation (HAE) Upgraded to "Buy" by Zacks Investment ResearchHaemonetics Corporation (HAE) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 25 at 7:52 PM
Comparing Meridian Bioscience (VIVO) & Haemonetics Corporation (HAE)Comparing Meridian Bioscience (VIVO) & Haemonetics Corporation (HAE)
www.americanbankingnews.com - October 25 at 4:26 AM
Frank Magliochetti - Examines the New Trend of Handheld MedicineFrank Magliochetti - Examines the New Trend of Handheld Medicine
www.nasdaq.com - October 25 at 3:24 AM
ETFs with exposure to Haemonetics Corp. : October 20, 2017ETFs with exposure to Haemonetics Corp. : October 20, 2017
finance.yahoo.com - October 20 at 11:07 PM
Haemonetics Corporation (HAE) Receives Average Rating of "Hold" from AnalystsHaemonetics Corporation (HAE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 19 at 2:56 AM
Robert E. Abernathy Joins Haemonetics Board of DirectorsRobert E. Abernathy Joins Haemonetics Board of Directors
finance.yahoo.com - October 19 at 2:44 AM
Contrasting Haemonetics Corporation (HAE) and Its CompetitorsContrasting Haemonetics Corporation (HAE) and Its Competitors
www.americanbankingnews.com - October 14 at 12:36 PM
Frank Magliochetti - Discusses the Rising Costs of Prescription Drugs in 2017Frank Magliochetti - Discusses the Rising Costs of Prescription Drugs in 2017
www.finanznachrichten.de - October 12 at 8:17 PM
Disposable Blood Bag Market - Global Opportunity Analysis and Industry Forecast, 2017-2023Disposable Blood Bag Market - Global Opportunity Analysis and Industry Forecast, 2017-2023
www.bizjournals.com - October 12 at 8:17 PM
Haemonetics Sets Date for Publishing 2nd Quarter and 1st Half Fiscal 2018 Results: November 7, 2017Haemonetics Sets Date for Publishing 2nd Quarter and 1st Half Fiscal 2018 Results: November 7, 2017
finance.yahoo.com - October 10 at 6:46 PM
Critical Contrast: AtriCure (ATRC) & Haemonetics Corporation (HAE)Critical Contrast: AtriCure (ATRC) & Haemonetics Corporation (HAE)
www.americanbankingnews.com - October 10 at 2:16 PM
ETFs with exposure to Haemonetics Corp. : October 9, 2017ETFs with exposure to Haemonetics Corp. : October 9, 2017
finance.yahoo.com - October 9 at 7:26 PM
Head to Head Analysis: Baxter International (BAX) versus Haemonetics Corporation (HAE)Head to Head Analysis: Baxter International (BAX) versus Haemonetics Corporation (HAE)
www.americanbankingnews.com - October 7 at 2:22 PM

SEC Filings

Haemonetics (NYSE:HAE) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Haemonetics (NYSE HAE) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.